Company

Mirai Bio

Mirai Bio uses machine learning and lipid formulations to optimize genetic medicine delivery.

About

Mirai Bio develops delivery systems for genetic medicines using machine learning and lipid formulations. Its platform supports the design of therapeutic cargo for applications including genome engineering, tRNA, mRNA, and DNA therapeutics. The company serves biotechnology and pharmaceutical firms. Based in Cambridge, US, it was founded by Hari Pujar. In September 2024, it raised USD 50 mn in Series A funding from Flagship Pioneering.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in